Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Investment analysts at Wedbush issued their FY2023 earnings estimates for Monte Rosa Therapeutics in a report released on Wednesday, February 14th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($2.63) per share for the year. Wedbush currently has a “Outperform” rating and […]
Analysts at Wedbush began coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price target points to a potential upside of 131.09% from the company’s current price. Separately, […]
Equities researchers at Wedbush initiated coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 131.09% from the company’s previous close. […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,360,000 shares, a decrease of 20.5% from the November 30th total of 2,970,000 shares. Currently, 7.5% of the company’s stock are sold short. Based on […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Freeline Therapeutics (NASDAQ:FRLN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown […]